P

Inventor

XU MINZHEN

US14 patents
⚠️ This page may combine multiple inventors who share the name “XU MINZHEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ANTIGEN EXPRESS INC

6 patents
US7179645B2Feb 20, 2007

Ii-Key/antigenic epitope hybrid peptide vaccines

ANTIGEN EXPRESS INC54 citations91
US6432409B1Aug 13, 2002

Hybrid peptides modulate the immune response

ANTIGEN EXPRESS INC24 citations91
US7205274B2Apr 17, 2007

Hybrid peptides modulate the immune response

ANTIGEN EXPRESS INC6 citations72
US6368855B1Apr 9, 2002

MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression

ANTIGEN EXPRESS INC11 citations72
US7935350B2May 3, 2011

Ii-key/Her-2/neu hybrid cancer vaccine

ANTIGEN EXPRESS INC4 citations61
US7541334B2Jun 2, 2009

Hybrid peptides modulate the immune response

ANTIGEN EXPRESS INC3 citations61

UNIV MASSACHUSETTS

3 patents
US5919639AJul 6, 1999

Ii peptide therapeutics to enhance antigen presentation

UNIV MASSACHUSETTS40 citations92
US5726020AMar 10, 1998

Inhibition of II synthesis

UNIV MASSACHUSETTS23 citations92
US6835382B2Dec 28, 2004

Ii peptide therapeutics to enhance antigen presentation

UNIV MASSACHUSETTS0 citations51

HUMPHREYS ROBERT

3 patents
US8815249B2Aug 26, 2014

Ii-key/antigenic epitope hybrid peptide vaccines

HUMPHREYS ROBERT8 citations81
US9289487B2Mar 22, 2016

II-key/antigenic epitope hybrid peptide vaccines

HUMPHREYS ROBERT4 citations65
US8889143B2Nov 18, 2014

Ii-key/HER-2/neu hybrid cancer vaccine

HUMPHREYS ROBERT0 citations49

XU MINZHEN

2 patents
US11389475B2Jul 19, 2022

Method for inducing an M1 dominated immune response and pharmaceutical compositions

XU MINZHEN0 citations57
US8748130B2Jun 10, 2014

Human papillomavirus / Ii-Key hybrids and methods of use

XU MINZHEN1 citations45